0.54Open0.30Pre Close1 Volume109 Open Interest0.50Strike Price54.00Turnover0.00%IV-3.70%PremiumJul 19, 2024Expiry Date0.58Intrinsic Value100Multiplier14DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.27Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Gossamer Bio Stock Discussion
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
• Oppenheimer has initiated Gossamer Bio at outperform expressing optimism on seralutinib, its inhaled tyrosine kinase inhibitor for pulmonary arterial hypertension (PAH).
• The firm has a $9 price target (~984% upside based on June 24 close).
• Analyst Andreas Argyrides said that the candidate's safety and efficacy profile makes it "a preferred choice among severe PAH patients who are not ad...
Gossamer Bio Inc: Eligible to Receive up to $146 Mln in Regulatory and $180 Mln in Sales Milestones
Gossamer Bio Published TORREY Phase 2 Results In Lancet Respiratory Medicine
Moomoo 24/7· just
No comment yet